Immunopathogenesis of multiple sclerosis: implications for treatment.
Waldron-Lynch
F
F
Hennessy
M J
MJ
D000328:Adult; D017677:Age Distribution; D017668:Age of Onset; D000368:Aged; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D007494:Ireland / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology*; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D016896:Treatment Outcome
D001323:Autoantibodies; D007166:Immunosuppressive Agents